Ziltivekimab meets primary endpoint in chronic kidney disease trial

In the RESCUE Phase II trial, ziltivekimab, an interleukin-6 (IL-6) inhibitor, improved levels of high-sensitivity C-reactive protein vs placebo. There was a 77%, 88% and 92% reduction in those receiving 7.5 mg, 15 mg and 30 mg vs a 4% reduction in those on placebo.

Source:

PharmaTimes